Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07220642 · ClinicalTrials.gov registry record · Phase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

A Phase 3 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.

Active
Registry status
Phase 3
Development phase
300
Enrollment target
20
Study locations

NCT07220642 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 300 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07220642, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Novo Nordisk A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.

Conditions Studied

Obesity Overweight

Interventions

  • DRUG Placebo
  • DRUG Cagrilintide

Study Locations (20)

Ontario

  • Hamilton Medical Rsrch Grp - Hamilton
  • Wharton Med Clin Trials - Hamilton
  • Milestone Research - London
  • Centricity Research Oshawa - Oshawa
  • Centricity Research Toronto - Toronto

Florida

  • Florida Inst For Clin Res LLC - Orlando
  • Oviedo Medical Research, LLC - Oviedo

Other

  • CIPREC Pueyrredon - Buenos Aires
  • CEDIC Centro de Investigación Clínica - CABA

New South Wales

  • Sydney Cardiometabolic Centre - Liverpool
  • Hunter Diabetes Centre - Merewether

California

  • Diablo Clinical Research, Inc. - Walnut Creek

Colorado

  • Univ of Colorado at Denver - Aurora

Illinois

  • Walgreens - Store 11760 - Oak Park

Indiana

  • Midwest Inst For Clin Res - Indianapolis

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-11-05
Est. Completion 2027-06-29
Phase Phase 3

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07220642

The ClinicalTrials.gov registry entry for NCT07220642 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07220642 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Ontario, Florida, Other.

Frequently Asked Questions

What is clinical trial NCT07220642 about?

NCT07220642 is a clinical study titled "Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide". This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided...

What is the current status of trial NCT07220642?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-11-05. Estimated completion is 2027-06-29.

What conditions does trial NCT07220642 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT07220642?

The interventions under investigation include: Placebo (DRUG), Cagrilintide (DRUG).

Who is sponsoring clinical trial NCT07220642?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07220642 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.